Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spike Glycoprotein S1 Subunit Receptor-Binding Domain (SARS-CoV-2) (RBD)
- Target
- RBD
- Molecular classification
- Glycoprotein, Viral protein, Receptor Binding Domain
01
Overview
The receptor-binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike glycoprotein is a critical component for viral entry into host cells. It directly binds to the human ACE2 receptor, initiating the process of membrane fusion. The RBD is a major target for neutralizing antibodies and is used in many COVID-19 vaccines to elicit protective immunity. Mutations in the RBD can affect ACE2 binding affinity, susceptibility to neutralizing antibodies, and overall viral pathogenicity.
- Other names
- SARS-CoV-2 Spike RBDSpike protein RBDReceptor-binding domain of SARS-CoV-2 spike glycoproteinS1 RBD
02
Mechanism of action
RBD is targeted by neutralizing antibodies that block binding to ACE2; Vaccines elicit an immune response against the RBD to prevent viral entry.
03
Biological functions
Receptor bindingViral entryImmune evasionAntigen presentation
04
Disease associations
InfectionCOVID-19Viral Pathogenesis
05
Safety considerations
Potential for antibody-dependent enhancement (ADE)Immune escape due to mutationsOff-target effects of monoclonal antibodies
06
Interacting drugs
Neutralizing antibodies
2 more in the full profile.
07
Biomarkers
Anti-RBD antibody levels (for vaccine efficacy and prior infection)ACE2 binding affinity
Beyond the preview
Go deeper on Spike Glycoprotein S1 Subunit Receptor-Binding Domain (SARS-CoV-2) (RBD).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spike Glycoprotein S1 Subunit Receptor-Binding Domain (SARS-CoV-2) (RBD).